Follow The Filings

AORT Artivion Inc.

Health Care, filed as ARTIVION INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $7.8M
  • 1 add

In 2026 Q2 First Eagle Investment Management added to Artivion.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (First Eagle Investment Management). Not free-float ownership.

  1. First Eagle Investment… Add 0.01%

Who owns AORT

Sorted by value, long equity only, as of 2026 Q2.

History
First Eagle Investment Management 0.01% Add +11.2% 346,573 $7.8M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AORT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AORT insider trades
  • None no insider bought on the open market
  • $7.2M sold by 7 insiders outside a trading plan
  • $4.9M sold by 4 insiders under 10b5-1 plans
  1. Andrew M Green SVP, Regulatory and Quality
    Sale
    $287K 11,480 shares at $24.97 22% of stake
    Traded Sep 10 Filed Sep 11
    ↗
  2. Andrew M Green SVP, Regulatory and Quality
    Sale
    $216K 8,003 shares at $27.03 13% of stake
    Traded Sep 2–3 Filed Sep 4
    ↗
  3. James P Mackin CEO
    Sale
    $2M 70,000 shares at $28.96 7.4% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  4. Jean F Holloway SVP, General Counsel
    Sale
    $28K 977 shares at $28.49 0.5% of stake
    Traded Aug 12 Filed Aug 12
    ↗
  5. Andrew M Green SVP, Regulatory and Quality
    Planned sale
    $911K 44,001 shares at $20.70 42% of stake
    Traded Jun 11 Filed Jun 15
    ↗
  6. Jean F Holloway SVP, General Counsel
    Sale
    $341K 8,962 shares at $38.00 4.6% of stake
    Traded Mar 4 Filed Mar 4
    ↗
  7. John E Davis Chief Commercial Officer
    Sale
    $226K 5,000 shares at $45.11 2.5% of stake
    Traded Dec 15, 2025 Filed Dec 17, 2025
    ↗
  8. James P Mackin CEO
    Planned sale
    $1.4M 30,921 shares at $45.46 3.7% of stake
    Traded Dec 3, 2025 Filed Dec 4, 2025
    ↗
  9. Jean F Holloway SVP, General Counsel
    Sale
    $331K 7,315 shares at $45.30 4.5% of stake
    Traded Dec 3, 2025 Filed Dec 4, 2025
    ↗
  10. James P Mackin CEO
    Planned sale
    $1.4M 30,921 shares at $45.56 3.7% of stake
    Traded Dec 2, 2025 Filed Dec 3, 2025
    ↗
  11. Marshall S. Stanton SVP, Clinical & MD Affair
    Sale
    $2.1M 47,376 shares at $45.04 51% of stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
    ↗
  12. Marshall S. Stanton SVP, Clinical & MD Affair
    Sale
    $675K 15,276 shares at $44.18 25% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
    ↗
  13. Elizabeth A Hoff Director
    Sale
    $189K 4,200 shares at $45.10 13% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
    ↗
  14. Jean F Holloway SVP, General Counsel
    Planned sale
    $577K 12,787 shares at $45.09 7.3% of stake
    Traded Nov 14–17 Filed Nov 18, 2025
    ↗
  15. John E Davis Chief Commercial Officer
    Planned sale
    $574K 12,787 shares at $44.92 6% of stake
    Traded Nov 14–17 Filed Nov 18, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 37 sales to cover taxes, 20 stock grants, 13 option exercises, 2 other transactions, and 1 gift.

Congress

2 members of Congress traded AORT in the last three years: 4 buys and 1 sale. 3 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Aug 20 filed Sep 10
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jul 16 filed Sep 4
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Oct 9, 2025 filed Nov 18, 2025
  4. Tina Smith D-MNSpouse Buy $50K–$100K Nov 16, 2023 filed Nov 20, 2023
  5. Tina Smith D-MNSpouse Buy $50K–$100K Nov 10, 2023 filed Nov 20, 2023

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 1.01,2.02,9.01 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $354M $388.54M $441.33M
Gross profit $229.18M $248.78M $284.23M
Gross margin * 64.7% 64.0% 64.4%
Net income -$30.69M -$13.36M $9.77M
Net margin * -8.7% -3.4% 2.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $280.67M $290.08M $358.08M
Total non-current assets * $511.73M $499.02M $526.71M
Total assets $792.4M $789.1M $884.8M
Total current liabilities $57.86M $66.82M $101.56M
Total non-current liabilities * $452.76M $446.08M $335.01M
Total equity $281.78M $276.2M $448.23M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $18.82M $22.24M $39.88M
Cash from investing -$0.502M -$28.19M -$42.04M
Cash from financing $0.865M $2.2M $11.28M
Net change in cash $19.59M -$5.48M $11.44M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf